EC Approval Expands Venclyxto Label in CLL, Adds New Combos

What happened

The European Commission has authorized expanded use of AbbVie's Venclyxto (venetoclax) in untreated chronic lymphocytic leukemia, adding combinations with acalabrutinib (with or without obinutuzumab) and ibrutinib, based on Phase 3 AMPLIFY, GLOW, and CAPTIVATE data. While this approval broadens the addressable CLL population and supports AbbVie's oncology pipeline, Venclyxto's contribution to overall revenue is relatively modest compared to immunology giants Skyrizi and Rinvoq. The DeepValue master report holds a WAIT rating with a base case of $235, driven by the immunology growth algorithm ($34.5B in 2026), which remains the dominant factor for the stock. This news does not materially alter the near-term revenue trajectory for AbbVie, as CLL market dynamics are competitive and Venclyxto faces long-established rivals. The approval is a positive but incremental regulatory win that underscores AbbVie's ability to extend existing drug lifecycles, yet it does not shift the key risk-reward equation centered on immunology execution.

Implication

Investors should view this EC approval as supportive but non-material to near-term fair value, given Venclyxto's $2.5B in 2025 net revenues (about 4% of total) and the fact that the new combinations are in a crowded CLL space. The primary catalysts remain the 2026 immunology framework (Skyrizi $21.5B, Rinvoq $10.1B) and the Rinvoq exclusivity runway to 2037. This news provides no evidence on immunology share capture or pricing headwinds, so the WAIT rating and attractive entry zone of $210 are unchanged. However, the approval does de-risk the oncology pipeline incrementally and could provide modest upside to the bull case ($255) if Venclyxto exceeds expectations. For now, the implied value range of $195-$255 remains intact, with the base case of $235 dependent on immunology outcomes.

Thesis delta

The thesis does not shift: AbbVie's valuation continues to be driven by the transition from Humira to Skyrizi/Rinvoq, and the Venclyxto label expansion is a positive but secondary development. The core underwrite remains execution on the 2026 immunology algorithm and Rinvoq duration, both of which are unaffected by this CLL approval. No change to the WAIT rating or price targets is warranted.